NEXT MOVE STRATEGY CONSULTING · MARKET INTELLIGENCE BRIEF
Heart Attack Diagnostics Market Strategic Outlook 2024–2030 · Investment, Innovation & Growth in Cardiovascular Diagnostics
Market 2023
Forecast 2030
USD 10.1
USD 17.7
B
Base-year market size (FY 2023)
B
USD 7.6B uplift (cumulative)
CAGR
Geographic Leader
8.4
North America
%
2024–2030 compounded growth rate
Dominant share · APAC = fastestgrowing
Executive Summary
Cardiovascular diagnostics are entering a structural growth phase driven by rising chronic-disease prevalence (74% of non-communicable mortality), technology-led detection (high-sensitivity troponin, AI-enabled imaging) and emerging wearable / remote monitoring use cases. The market is on track to nearly double by 2030, opening acquisition, partnership and platform-investment opportunities across the diagnostic value chain.
ECG & 12-lead output · Core diagnostic modality
Industry Ecosystem
Imaging modalities
·
Cardiac biomarkers
·
ECG / EKG platforms
·
Cath-lab angiography
·
AI-assisted diagnostics
·
Wearables & remote monitoring Cardiac biomarkers and wearable sensors are positioned as the principal upstream opportunity, while hospital & clinic end-users remain the dominant demand channel.
© Next Move Strategy Consulting · Heart Attack Diagnostics Market · 2026
01 / 05 · COVER & LANDSCAPE
MARKET SIZING · 02 / 05
From USD 10.1B to USD 17.7B USD 7.6 billion in cumulative uplift · 7-year forecast at 8.4% CAGR
MARKET VALUE TRAJECTORY (USD BILLION)
17.9M annual CVD deaths globally the leading cause of NCD mortality (WHO)
41M / 74% annual NCD deaths worldwide 74% of total global mortality (WHO)
697K U.S. deaths from heart disease in 2020 the U.S. leading cause of death (CDC)
KEY MARKET DYNAMICS
Chronic-disease load. 6 of 10 U.S. adults have a chronic disease
Geographic mix. North America dominant; Asia-Pacific fastest-
(CDC 2022) directly enlarging the addressable diagnostic
growth driven by India (+32,457 heart-attack deaths in 2022).
population. Tech-led detection. High-sensitivity troponin, point-of-care tests
Constraints. High cost of diagnosis and limited rural infrastructure temper adoption; remote-monitoring wearables are the offset.
and advanced imaging shorten time-to-diagnosis. Survival economics. Early MI detection lifts intervention success and reduces downstream cost of care.
© Next Move Strategy Consulting · Heart Attack Diagnostics Market · 2026
02 / 05 · MARKET SIZE & GROWTH
GROWTH DRIVERS · 03 / 05
What Is Powering an 8.4% CAGR Through 2030? Four structural demand drivers, three high-growth segments, and one regional accelerator
PRIMARY DEMAND DRIVERS
01
02
03
Chronic-Disease Prevalence
Diagnostic-Tech Innovation
Rising MI Burden
Diabetes, obesity, hypertension & high cholesterol are rising across every major geography — direct upstream drivers of MI incidence.
High-sensitivity troponin assays, point-of-care tests and AI-enabled imaging compress timeto-diagnosis and lift clinical confidence.
Cardiovascular diseases kill 17.9M people annually; heart attack remains the largest single-disease driver of diagnostic demand. #1 NCD killer
74% of global deaths
HS-troponin + POC
are non-communicable diseases (WHO)
dominant technology pipeline
17.9M annual CVD deaths (WHO)
Regional Accelerator
04
Asia-Pacific
Cardiac Biomarkers + Wearable Sensors Combined biomarker panels and continuous wearable sensors enable remote monitoring, earlier intervention and reduced per-patient cost opening the most material upside in the 2024–2030 forecast window.
Fastest-growing region led by India (+32,457 heartattack fatalities in 2022), China and Thailand. Active local presence of Hitachi Healthcare and Philips supports roll-out capacity.
Largest opportunity vector Upstream demand-shift from episodic to continuous cardiac monitoring
Philips Mini TEE transducer received FDA clearance Jan 2024
HIGH-GROWTH SEGMENTS (TEST TYPE)
SEGMENT
High-Sensitivity Troponin Rapid, quantitative MI rule-out — center of biomarker-led growth.
SEGMENT
ECG / EKG Platforms 12-lead + AI-assisted interpretation; hospital & ambulatory standard.
SEGMENT
AI-Enabled Cardiac Imaging CT, echo & MRI with motion-free capture, 3D TEE, real-time guidance.
INVESTOR TAKEAWAY
Underwrite the shift from episodic to continuous monitoring. Diagnostic revenue mixes toward wearables, biomarker panels and AI image interpretation.
Position in the APAC tier-2 hospital segment. Underpenetrated cath-lab and CT capacity in India & SE Asia supports installed-base expansion through 2030. Cost-down plays (POC, remote echo) offset rural-infrastructure risk the headline market constraint flagged in the source report.
© Next Move Strategy Consulting · Heart Attack Diagnostics Market · 2026
03 / 05 · GROWTH DRIVERS & OPPORTUNITIES
COMPETITIVE LANDSCAPE · 04 / 05
15 Profiled Players · 3 Strategic Plays Market share data available for 10 of 15 leaders · 28 geographies covered
LEADING COMPANY ROSTER (TIER 1 — 9 OF 15)
TIER · IMAGING SYSTEMS
TIER · DIAGNOSTICS IVD
TIER · IMAGING SYSTEMS
Siemens Healthcare AG
Abbott Laboratories Inc.
GE Healthcare
TIER · IMMUNOASSAY IVD
TIER · PHARMA + DX
TIER · IMAGING/AI
Beckman Coulter Inc.
F. Hoffmann-La Roche Ltd
Koninklijke Philips N.V.
TIER · IMAGING SYSTEMS
TIER · AI ULTRASOUND
TIER · GENOMIC DX
Hitachi Healthcare
Caption Health
Cardio Diagnostics Holdings
Plus 6 additional players: Schiller AG · Midmark Corporation · Bio-Rad Laboratories · Welch Allyn · Pfizer Inc. · Life Sign LLC
KEY STRATEGIC MOVES SHAPING THE MARKET
PRODUCT LAUNCH
PARTNERSHIP
AI PLATFORM
Feb 2023
Nov 2021
Mar 2021
Caption Health × Ultromics AIpowered echo diagnostics
Philips AI-enabled Precise Suite on Incisive CT
Collaboration to deliver AI-driven heart-disease
Motion-free cardiac image capture, automated
Measures proteins associated with coronary
detection and management tools to healthcare
patient positioning and real-time interventional
heart disease; positions the company upstream
providers across the U.S.
guidance onto a single CT platform.
Cardio Diagnostics launches blood test for early CHD detection
of hospital-based MI diagnostics.
WINNING STRATEGIES (BY FREQUENCY)
© Next Move Strategy Consulting · Heart Attack Diagnostics Market · 2026
04 / 05 · COMPETITIVE SCENARIO
NEXT MOVE STRATEGY CONSULTING · 05 / 05 · THANK YOU
Thank You Connect with us for the full market study sizing, segmentation by country, 15-company competitive deep-dive, and strategic recommendations for the cardiovascular diagnostics cycle. CONTACT NEXT MOVE STRATEGY CONSULTING
Phone
Official Website
+1 (857) 758-5017
info@nextmsc.com
nextmsc.com
Mon–Fri · 9:00–18:00 EST
Report inquiries & custom research
Full report & methodology
gen-dedup-be1ff4091cf3812f0635033918e910ee.png
Get the Full Heart Attack Diagnostics Market Report Click here for the complete report — nextmsc.com/report/heart-attack-diagnostics-market
FOLLOW US gen-dedup-bd4efa1fe9186bbcca9354693e52c809.png
in
f
/company/ next-move-strategy-consulting
/Next-MoveStrategy-Consulting
𝕏
◐
YouTube
Twitter / X
/channel/UCJuVRxfBo -Dsog7BgDE4uPQ
@nextmsc
@nextmsc
Methodology. Sourced from Next Move Strategy Consulting's published market research report on the Heart Attack Diagnostics Market; supplemented with WHO and CDC public health data. Custom research requests, country-level scoping and additional company profiles are available on request. © 2026 Next Move Strategy Consulting. All rights reserved.
© Next Move Strategy Consulting · Heart Attack Diagnostics Market · 2026
05 / 05 · THANK YOU & CONTACT